Amedisys (AMED) Stock Forecast, Price & News

Amedisys (NASDAQ:AMED) Frequently Asked Questions

Is Amedisys a buy right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last twelve months. There are currently 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Amedisys stock.
View analyst ratings for Amedisys or view top-rated stocks.

Are investors shorting Amedisys?

Amedisys saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 1,210,000 shares, a decline of 16.6% from the April 30th total of 1,450,000 shares. Based on an average daily volume of 330,000 shares, the days-to-cover ratio is presently 3.7 days. Approximately 3.8% of the shares of the stock are short sold.
View Amedisys' Short Interest.

When is Amedisys' next earnings date?

Amedisys is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Amedisys.

How were Amedisys' earnings last quarter?

Amedisys, Inc. (NASDAQ:AMED) posted its earnings results on Wednesday, April, 27th. The health services provider reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.12. The health services provider had revenue of $545.26 million for the quarter, compared to the consensus estimate of $557.81 million. Amedisys had a trailing twelve-month return on equity of 19.37% and a net margin of 8.59%. During the same quarter last year, the business earned $1.54 EPS.
View Amedisys' earnings history.

How will Amedisys' stock buyback program work?

Amedisys announced that its Board of Directors has authorized a stock repurchase plan on Wednesday, August 4th 2021, which permits the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to reacquire up to 1.2% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's management believes its stock is undervalued.

What guidance has Amedisys issued on next quarter's earnings?

Amedisys issued an update on its FY22 earnings guidance on Wednesday, April, 27th. The company provided EPS guidance of $5.23-$5.45 for the period, compared to the consensus estimate of $5.33. The company issued revenue guidance of $2.330-$2.365 billion, compared to the consensus revenue estimate of $2.36 billion.

What price target have analysts set for AMED?

15 analysts have issued twelve-month price objectives for Amedisys' shares. Their forecasts range from $117.00 to $220.00. On average, they anticipate Amedisys' stock price to reach $189.80 in the next year. This suggests a possible upside of 61.5% from the stock's current price.
View analysts' price targets for Amedisys or view top-rated stocks among Wall Street analysts.

Who are Amedisys' key executives?

Amedisys' management team includes the following people:

• Mr. Christopher T. Gerard, CEO, Pres & Director (Age 55, Pay $872.7k) (LinkedIn Profile)
• Mr. Scott G. Ginn, Exec. VP & CFO (Age 53, Pay $779.31k) (LinkedIn Profile)
• Mr. David L. Kemmerly, Chief Legal & Gov. Affairs Officer (Age 59, Pay $547.27k) (LinkedIn Profile)
• Mr. Pete Hartley, CTO & Sr. VP of Bus. Operations Systems
• Mr. Michael P. North, Chief Information Officer (Age 57) (LinkedIn Profile)
• Ms. Denise Bohnert, Chief Compliance Officer (Age 44)
• Kendra Kimmons, VP of Marketing & Communications & Media Relations
• Ms. Megan Ambers, Interim Chief HR Officer
• Mr. John Nugent, Chief Acquisitions Officer
• Ms. Janet Britt, Sr. VP of Billing & Collections

What is Paul B. Kusserow's approval rating as Amedisys' CEO?

297 employees have rated Amedisys CEO Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among Amedisys' employees.

Who are some of Amedisys' key competitors?

Some companies that are related to Amedisys include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Chemed (CHE), R1 RCM (RCM), LHC Group (LHCG), AMN Healthcare Services (AMN), CorVel (CRVL), MEDNAX (MD), Tivity Health (TVTY) and Cross Country Healthcare (CCRN).
View all of AMED's competitors.

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD).

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Who are Amedisys' major shareholders?

Amedisys' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.96%), Vanguard Group Inc. (9.36%), Wellington Management Group LLP (5.76%), Riverbridge Partners LLC (5.21%), JPMorgan Chase & Co. (4.25%) and Mackenzie Financial Corp (2.94%). Company insiders that own Amedisys stock include Bruce D Perkins, Bruce D Perkins, Christopher Gerard, David L Kemmerly, David L Kemmerly, Denise M Bohnert, Michael Paul North, Richard A Lechleiter, Scott G Ginn and Sharon Brunecz.
View institutional ownership trends for Amedisys.

Which major investors are selling Amedisys stock?

AMED stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., BNP Paribas Arbitrage SA, Ensign Peak Advisors Inc, William Blair Investment Management LLC, Polar Capital Holdings Plc, TD Asset Management Inc., First Trust Advisors LP, and Integral Health Asset Management LLC. Company insiders that have sold Amedisys company stock in the last year include Bruce D Perkins, Christopher Gerard, David L Kemmerly, and Scott G Ginn.
View insider buying and selling activity for Amedisys or view top insider-selling stocks.

Which major investors are buying Amedisys stock?

AMED stock was purchased by a variety of institutional investors in the last quarter, including Mackenzie Financial Corp, JPMorgan Chase & Co., Frontier Capital Management Co. LLC, Twin Tree Management LP, BlackRock Inc., Bank of New York Mellon Corp, Riverbridge Partners LLC, and Principal Financial Group Inc.. Company insiders that have bought Amedisys stock in the last two years include Bruce D Perkins, and Richard A Lechleiter.
View insider buying and selling activity for Amedisys or or view top insider-buying stocks.

How do I buy shares of Amedisys?

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $117.53.

How much money does Amedisys make?

Amedisys has a market capitalization of $3.83 billion and generates $2.21 billion in revenue each year. The health services provider earns $209.07 million in net income (profit) each year or $5.81 on an earnings per share basis.

How many employees does Amedisys have?

Amedisys employs 21,000 workers across the globe.

When was Amedisys founded?

Amedisys was founded in 1982.

What is Amedisys' official website?

The official website for Amedisys is www.amedisys.com.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at (225) 292-2031, via email at [email protected], or via fax at 225-292-8163.